SCHEMBL4237351

SCHEMBL4237351

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Oc4cc(F)c(NC(=O)NC(CC)COC)cc4OC)cc3)cc2C)CC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
MCHR1 Q99705 2/20 0.38
NAMPT P43490 1/20 0.36
HTR4 Q13639 1/20 0.36
FGFR1 P11362 2/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ERBB2 P04626 2/20 0.36
KDR P35968 2/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
POLB P06746 1/20 0.35
EGFR P00533 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4683749 0.99 LMNA (0.39) LMNAMAPTTAS1R3TAS1R1MCHR1
SCHEMBL4233744 0.96 MAPT (0.39) LMNAMAPTTAS1R3TAS1R1MCHR1
SCHEMBL4236270 0.94 MCHR1 (0.39) LMNAMAPTTAS1R3TAS1R1MCHR1
SCHEMBL4236713 0.93 MCHR1 (0.41) LMNAMAPTTAS1R3TAS1R1MCHR1
SCHEMBL4234434 0.92 LMNA (0.40) LMNAMAPTMCHR1HTR4FGFR1
SCHEMBL4232148 0.91 MCHR1 (0.40) LMNAMAPTTAS1R3TAS1R1MCHR1
SCHEMBL4236667 0.91 TAS1R3 (0.40) LMNAMAPTTAS1R3TAS1R1MCHR1
SCHEMBL4229393 0.90 MCHR1 (0.38) MAPTTAS1R3TAS1R1MCHR1MEN1
SCHEMBL4228743 0.89 MCHR1 (0.41) MCHR1RAB9AKDRFLT1FLT4
SCHEMBL4236322 0.89 FGFR1 (0.43) LMNAMAPTTAS1R3TAS1R1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R LMNA 2227/4885MAPT 1398/4885TAS1R3 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.